Page results
-
This page provides general information about care of wounds following spinal surgery.
-
The thyroid and endocrine surgery department at UCLH is one of the largest endocrine surgical services in the UK. We provide high level of care for patients who require surgical advice and management of benign and malignant endocrine conditions affecting the thyroid, parathyroids and adrenal glands. We are also specialised in the treatment of patients who require re-operative management.
-
This page has been written for patients who are having radiotherapy or proton beam therapy to the oesophagus.
-
This page provides general information about the procedure called anterior cervical discectomy.
-
Once you have completed treatment for cancer at UCLH you will enter a period of follow-up care. Follow-up is an important way of monitoring your health.
-
Coping with nausea patient information page.
-
Gastro-oesophageal reflux (GOR) is the effortless regurgitation of feeds/milk. It affects over 40% of babies.
-
This page provides information on the purpose of diet in helping to manage the symptoms of Crohn’s disease in the remission phase.
-
Information about Lutetium-177 PSMA radionuclide therapy for metastatic or treatment-resistant prostate cancer
-
Our Proton Beam Therapy (PBT) department can treat up to 650 NHS patients per year from across the south of the UK when we are at full capacity. We provide treatment for a wide range of child and teenage cancers and complex adult cancers.
File results
-
FOI/2023/0327 - NHS long-term plan/ prevention strategy
-
FOI/2023/0326 - Risk management system reporting rates for adverse events
-
FOI/2023/0323 - Medications/ treatment for dermatology and respiratory medicine
-
FOI/2023/0319 - Multiple Sclerosis (MS) treatment/ medication for any diseases
-
FOI/2023/0315 - Menopause Lead at the Trust
-
FOI/2023/0313 - Consent, confidentiality and information sharing in mental healthcare and suicide
-
FOI/2023/0310 - Biologic treatment/ medicines in dermatology
-
FOI/2023/0308 - Treatment for biologic and biosimilar products within rheumatology
-
FOI/2023/0304 - Chronic lymphocytic leukaemia treatments
-
FOI/2023/0007 - Outpatient activity for 2022